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Abstract
Bispecific antibodies as well as non-immunoglobulin based bispecific affinity proteins are considered to have a very high
potential in future biotherapeutic applications. In this study, we report on a novel approach for generation of extremely
small bispecific proteins comprised of only a single structural domain. Binding to tumor necrosis factor-a (TNF-a) was
engineered into an albumin-binding domain while still retaining the original affinity for albumin, resulting in a bispecific
protein composed of merely 46 amino acids. By diversification of the non albumin-binding side of the three-helix bundle
domain, followed by display of the resulting library on phage particles, bispecific single-domain proteins were isolated using
selections with TNF-a as target. Moreover, based on the obtained sequences from the phage selection, a second-generation
library was designed in order to further increase the affinity of the bispecific candidates. Staphylococcal surface display was
employed for the affinity maturation, enabling efficient isolation of improved binders as well as multiparameter-based
sortings with both TNF-a and albumin as targets in the same selection cycle. Isolated variants were sequenced and the
binding to albumin and TNF-a was analyzed. This analysis revealed an affinity for TNF-a below 5 nM for the strongest
binders. From the multiparameter sorting that simultaneously targeted TNF-a and albumin, several bispecific candidates
were isolated with high affinity to both antigens, suggesting that cell display in combination with fluorescence activated
cell sorting is a suitable technology for engineering of bispecificity. To our knowledge, the new binders represent the
smallest engineered bispecific proteins reported so far. Possibilities and challenges as well as potential future applications of
this novel strategy are discussed.
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Introduction
Monoclonal antibodies have been widely used in nearly all areas
of life science for over three decades and represent a growing class
of agents also in the clinics, mainly due to their generally high
specificity and excellent pharmacokinetic properties. Today,
regulatory authorities have approved over 20 monoclonal
antibodies for therapeutic or diagnostic use [1,2]. In addition to
full-length monoclonal antibodies, smaller antibody derivatives
(e.g. scFvs and Fab fragments) as well as entirely new protein
architectures [3,4,5] have been investigated for similar purposes.
The non-immunoglobulin based affinity proteins are in general
derived from single domain scaffolds with attractive biophysical
properties, such as high stability and solubility. The size of these
alternative scaffolds is typically smaller compared to antibodies,
which provides means for cost-efficient production in bacteria. For
the smallest scaffolds there is also a possibility to use solid-phase
peptide synthesis for production, enabling site-specific conjugation
of non-biological groups (e.g. chelators and payloads) as well as
engineering of new physicochemical properties into the agent [6].
For molecular imaging (e.g. in cancer prognostic and diagnostic
applications), the reduced size of such alternative scaffolds
generally results in an improved tumor-to-blood contrast due to
the rapid tumor penetration and in vivo clearance rate [7,8,9].
Furthermore, the small size and straightforward recombinant
manipulation make alternative affinity proteins an excellent choice
for generation of bi- and multispecific molecules [10]. Several of
the reported alternative scaffolds are also based on domains that
are found as repetitive elements in natural proteins (e.g. affibody
molecules that are originally derived from protein A [11]),
supporting the strategy of using them in bi- and multispecific
constructs. However, although fusing such domains into multi-
specific chains is relatively straightforward, it also has an impact on
the overall size of the final molecule, which might negatively
influence some of the favorable properties.
In this study, we take the concept of bispecific affinity proteins
one step further by engineering the specific targeting directly into
an albumin-binding domain, thus creating a single-domain
bispecific affinity protein. In order to engineer such a small
protein domain with dual affinities, an alkali-stabilized variant [12]
of a natural albumin-binding domain (ABD) was chosen as
scaffold. ABD is a 46 amino acid, three-helical bundle protein [13]
with the albumin-binding site mainly in the second helix
[14,15,16]. Hence, eleven amino acids in helix one and three
were chosen for randomization and the resulting library was
displayed on phage particles for subsequent selections [17]. In this
project, the objective was to select bispecific binders that were able
to interact with TNF-a, and still retain the affinity towards human
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fusion of the molecule of interest to albumin-binding domains has
been shown to provide substantial half-life extensions for various
recombinant proteins in vivo [18,19]. TNF-a is a pleiotropic
proinflammatory cytokine that plays an important pathogenic role,
particularly in inflammatory disorders [20]. Both the cell-
associated and the secreted forms of TNF-a are biologically active
in the form of homotrimers and inhibition of TNF-a has proven to
be an effective therapy for a number of inflammatory diseases (e.g.
rheumatoid arthritis). Several protein-based antagonists are
currently approved for clinical use [2]. Engineering TNF-a-
binding into a small protein with an intrinsic extended half-life
may reduce the dosing frequency and thereby the associated
treatment cost. This strategy, hence, aims to combine the
advantages of small size (e.g. efficient production in a bacterial
host or by chemical synthesis) with the long persistence in the
circulation that is typical for antibodies.
In order to succeed with the challenging effort of engineering
such bispecific affinity proteins, phage display was used for
selection of first-generation TNF-a specific binders from the
combinatorial ABD-library. In the following lead optimization,
cell display in combination with fluorescence activated cell sorting
(FACS) was utilized for affinity maturation as well as efficient
multiparameter sorting of bispecific variants that showed strong
binding to TNF-a while still retaining their affinity to HSA. In
summary, our results demonstrate that it is possible to engineer
two high affinity interactions into a small protein domain, hence
rendering it bispecific without increasing the overall size, and the
investigation also underlines the power of using different display
technologies for different tasks in the engineering process.
Materials and Methods
Labeling of TNF-a
TNF-a (ProSpec-Tany TechnoGene Ltd, Rehovot, Israel) at a
concentration of 0.15 mg ml
21 was biotinylated at room
temperature (RT) using a 50-fold molar excess of EZ-Link
TM
Sulfo-NHS-LC-Biotin (Pierce, IL, USA) in phosphate buffered
saline (PBS; 150 mM phosphate, 150 mM NaCl, pH 7.4). After
1 h incubation, an excess of glycine was added and the mixture
was dialyzed against PBS over night (ON) at 4uC. The
biotinylation was evaluated both by mass spectrometry and by
immobilization on streptavidin-coated paramagnetic beads (Dy-
nabeadsH M-280, Streptavidin, Dynal A.S., Oslo, Norway)
followed by sodium dodecyl sulphate polyacrylamide gel electro-
phoresis (SDS-PAGE).
Phage display selection
TNF-a-binding molecules were selected by phage display from
a combinatorial library based on an alkali-stabilized albumin-
binding domain [17]. In the library (,10
7 variants), 11 amino acid
positions have been diversified by an NNK-degeneracy resulting in
32 codons encoding all 20 amino acids and the amber stop codon
(TAG) in each randomized position. In the first round of selection,
2.2?10
9 E. coli cells (RRIDM15 [21]) carrying the phagemid ABD-
library were inoculated to 500 ml of tryptic soy broth supple-
mented with yeast extract (TSB+YE; Merck, Darmstadt, Ger-
many), 2% glucose and 100 mgm l
21 ampicillin and grown to an
OD600 nm of 0.8. An aliquot of the cell culture (10 ml) was
incubated with a 20-fold excess of helper phage (M13K07; New
England Biolabs, MA, USA) for 30 min at 37uC. Infected cells
were collected by centrifugation and used to inoculate 500 ml of
fresh TSB+YE supplemented with 100 mgm l
21 ampicillin, 50 mg
ml
21 kanamycin and 1 mM isopropyl b-D-thiogalactoside (IPTG;
Apollo Scientific, Derbyshire, UK). Following ON cultivation,
phages were isolated by two successive precipitation steps using
ice-cold polyethylene glycol/sodium chloride (20% PEG6000/2.5
M NaCl). Phages were resuspended in PBS containing 0.1%
Tween 20 and 3% BSA (TPBSB 3%) before being subjected to
selection. For the last two rounds the volume of the ON culture
was decreased to 100 ml.
Phages (5?10
12 in the first round and a 1000-fold excess
compared to the number of eluted phages in the following rounds)
were transferred to a tube (Protein LoBind microcentrifuge tube;
Eppendorf, Hamburg, Germany) blocked with PBS containing
0.1% Tween 20 and 5% BSA (TPBSB 5%) containing 0.2 mg
neutravidin coated beads (REGEN beads, Dynal A.S.; coated with
neutravidin according to supplier’s recommendations) in 0.5 ml
TPBSB 3%. After negative pre-selection for 30 min, the
supernatant was transferred to a new tube containing 150 nM of
biotinylated TNF-a (all stated concentrations of TNF-a refer to
monomer, 17351 g mol
21) in a total volume of 1 ml TPBSB 3%
followed by incubation for 2 h at RT. The mixture was transferred
to a new tube containing washed and blocked neutravidin-coated
paramagnetic beads, and incubated for 15 min to capture the
complexes. The target concentration was decreased for each cycle
(150–20 nM branched into four parallel tracks) whereas the
number of washes and percentage of Tween 20 in the TPBSB 3%
used for washing was increased. The same washing procedure as
was used in the selection was also employed during pre-selection.
For the last wash, a new blocked tube was used and the washing
solution was changed to PBS. Bound phages were eluted by an
addition of 500 ml 0.05 M glycine-HCl pH 2.2 and the eluate was
neutralized with 50 ml 1 M Tris-HCl pH 8.0 and 450 ml PBS
before it was used to infect a 200 ml log phase culture of
RRIDM15 E. coli for 30 min at 37uC. Cells were harvested by
centrifugation and spread on tryptone yeast extract agar plates
supplemented with 2% glucose and 100 mgm l
21 ampicillin. After
ON incubation, the cells were collected and used to inoculate new
TSB+YE medium, thereby starting the next round of selection.
DNA-sequencing and subcloning
Phagemid inserts from individual clones from the third and
fourth round of panning were PCR-amplified and sequenced with
specific primers and Big Dye terminators (Amersham Biosciences,
Uppsala, Sweden). Fragments were analyzed on an ABI PrismH
3700 DNA sequencer (Applied Biosystems, Foster City, CA). The
same procedure was used to verify the sequences of DNA-
fragments subcloned to the expression vector and cell-surface
display vector.
Phagemids were purified from small-scale E. coli cultivations by
EZNA plasmid purification kit (Omega Biotech, Victoria, Canada).
ABD-inserts were PCR-amplified with primers introducing restric-
tion sites for XhoI and EcoRI. The fragments were purified with
MinElute PCR purification kit (Qiagen, Solna, Sweden) followed by
restriction (XhoI and EcoRI; Fermentas). The expression vector,
containing both a His6-tag and an inducible promoter, was
prepared by plasmid preparation from RRIDM15 E. coli, digested
with the same enzymes and purified by preparative gel electropho-
resis on a 1% agarose gel. After purification, the fragments were
ligated with the vector using T4 DNA ligase (Fermentas) and
transformed to RRIDM15 E. coli. DNA sequences were verified
followed by plasmid preparation and transformation to E. coli
Rosetta (DE3) (Novagen, WI, USA) for protein production.
Expression and purification of ABD-molecules
Single colonies were grown in 10 ml TSB medium containing
50 mgm l
21 kanamycin and 20 mgm l
21 chloramphenicol at 37uC
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ON-culture and grown to log phase followed by induction of
protein expression by addition of IPTG to a final concentration
of 1 mM. The cultivations were incubated at 25uC ON and
harvested by centrifugation (2700 g, 15 min, 4uC). The pellets
were resuspended in 10 ml wash buffer (50 mM sodium
phosphate, 6 M Urea, 300 mM NaCl, pH 7.5) and disrupted by
sonication (Vibra Cell; Sonics and materials Inc., Danbury, CT,
USA). Proteins were recovered from the supernatant after a
subsequent centrifugation to remove cell debris (10000 g, 20 min,
4uC). The samples were filtered (0.45 mm) and loaded on a 1 ml
Talon metal affinity resin column (Clontech Laboratories, CA,
USA) equilibrated with eight column volumes (CV) of wash buffer.
The column was washed with ten CV of wash buffer followed by
elution in ten (1 ml) fractions (50 mM NaAc, 6 M Urea, 100 mM
NaCl, 30 mM HAc, pH 4.5). Protein concentrations were
estimated from absorbance measurements at 280 nm (Eppendorf
Biophotometer) and the most concentrated fractions were
analyzed by SDS-PAGE on Novex Bis-Tris 4–12% gradient gels
using the Novex system (Invitrogen, CA, USA). Buffer exchange
was done by extensive dialysis at 4uC against HEPES buffered
saline (HBS-EP; 10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA,
0.05% P20, pH 7.4). Concentrations were determined by amino
acid analysis (Aminosyraanalyscentralen, Uppsala, Sweden) and
molecular weights were verified by liquid chromatography
electrospray ionization mass spectrometry (LC-ESI-MS) on a
6520 Accurate Mass Q-TOF LC/MS (Agilent Technologies, CA,
USA).
Biosensor analysis of first generation binders
Selected ABD-variants were screened for binding to HSA and
TNF-a using surface plasmon resonance (SPR) with a BIAcoreH
2000 instrument (Biacore, Uppsala, Sweden). HSA and TNF-a
(both at 10 mgm l
21 in 10 mM NaAc, pH 4.5) were immobilized
(2000 response units (RU) each) on a Biacore CM5 sensor chip by
standard amine coupling. ABD-variants were serially injected over
both flow cells at concentrations ranging from 1–5 mM with a flow
rate of 50 ml min
21 at 25uC using HBS-EP as running buffer. The
surfaces were regenerated between injections using 10 ml pulses of
10 mM HCl. The response from a reference flow cell was
subtracted and the results were analyzed using BIAevaluation 3.2
software.
The two candidates that showed binding to TNF-a in the
screening (ABDTNF1 and ABDTNF2) were immobilized, by amine
coupling by the procedure described above, to 400 RU each on a
new CM5 chip. TNF-a was injected (50 ml min
21 at 25uC using
HBS-EP as running buffer) at concentrations ranging from 3.2–
9960 nM. Injections were performed in duplicates and the kinetic
constants (ka and kd) were determined using BIAevaluation 3.2
software. To determine the affinity to HSA, both ABD-variants as
well as the non-randomized ABD were injected in duplicates, at
concentrations ranging from approximately 1–3000 nM (up to
250 nM for ABD), over a surface immobilized with HSA (2000
RU). Kinetic constants were determined as above and equilibrium
responses (RU) from all experiments were fitted to a 1:1 binding
model using GraphPad Prism in order to determine the KD values.
Subcloning to staphylococcal display vector
The gene sequences encoding the non-randomized ABD and
the two selected bispecific ABD-variants were PCR-amplified from
their phage display vector constructs and ligated to a modified
version of the previously described staphylococcal display vector
pSCZ1 [22]. In the new vector (denoted pSCABD1), the albumin-
binding protein (ABP) that was previously used for normalization
of surface expression was replaced with a dimeric construct of an
IgG-binding domain (Z2) derived from staphylococcal protein A.
E. coli RR1DM15 was used as host for plasmid construction and
preparation, and the constructs were transformed to electrocom-
petent Staphylococcus carnosus TM300 according to previously
described protocol [23].
Cell labeling and flow-cytometric analysis
Staphylococcal cells displaying ABD-variants were inoculated to
10 ml TSB+YE with 10 mgm l
21 chloramphenicol and grown ON
at 37uC and 150 rpm. From ON cultures, approximately 10
6 cells
were washed with 1 ml PBS supplemented with 0.1% PluronicH
F108 NF Surfactant (PBSP; pH 7.4; BASF Corporation, Mount
Olive, NJ). The cells were pelleted by centrifugation (3500 g, 4uC,
6 min) and resuspended in 100 ml of PBSP containing twelve
different concentrations of biotinylated TNF-a (4.3–12900 nM) or
fluorophore-conjugated HSA (1.25–2500 nM; 10–20000 nM for
ABDTNF1). Equilibrium binding was reached by incubation at RT
for 1 h with gentle mixing. The cells were washed with 1 ml ice-
cold PBSP, followed by incubation on ice in 100 ml ice-cold PBSP
containing 1.25 mgm l
21 streptavidin-Alexa Fluor 488 conjugate
(Invitrogen) for 15 min (for HSA-binding the secondary incuba-
tion was omitted). Following one wash with 1 ml ice-cold PBSP,
cells were resuspended in 300 ml ice-cold PBSP prior to flow-
cytometric analysis. The mean fluorescence intensity (MFI) was
measured using a FACS Vantage SE (BD Biosciences, San Jose,
CA) flow cytometer. MFI data was fitted to a 1:1 binding model
using GraphPad Prism in order to determine the KD values.
Second-generation library construction and cloning
Two different degenerate oligonucleotides (Scandinavian Gene
Synthesis AB, Ko ¨ping, Sweden), encoding helix one and helix
three, respectively, with complementary regions encoding the non-
randomized second helix of ABD were annealed and extended by
six cycles of PCR using AmpliTaqGold DNA polymerase (Applied
Biosystems). Flanking restriction sites for XhoI and NheI were
introduced in an additional PCR-reaction (15 cycles) using a new
primer pair. The PCR-products were purified with QIAquick
PCR Purification Kit (Qiagen) according to the supplier’s
recommendations. The purified pool of randomized library
fragment was digested with restriction enzymes XhoI and NheI
(New England Biolabs) and purified as above. The staphylococcal
display vector, pSCABD1, was prepared from E. coli RR1DM15
and purified using Jetstar Maxi Kit (Genomed, Bad Oeynhausen,
Germany). The vector was digested with the same enzymes and
purified using preparative gel electrophoresis on a 1% agarose gel.
Ligation of pSCABD1 with the randomized library fragments was
performed at a 1:20 molar ratio of vector to fragment using T4
DNA ligase (New England Biolabs). The ligation mixture was
purified using QIAquick Gel Extraction Kit according to the
supplier’s recommendations prior to transformation to electro-
competent E. coli DH5a cells. Individual clones, plated directly
after transformation, were PCR-amplified for sequence verifica-
tion using BigDye Thermo Cycle Sequencing reactions and an
ABI PrismH 3700 instrument (Applied Biosystems). Plasmids were
prepared from ON cultures of E. coli using Jetstar Maxi Kit
(Genomed) and transformed to electrocompetent S. carnosus as
described above. The staphylococcal library is hereinafter denoted
Sc:ABDTNFlib.
Cell labeling and FACS
Cells, approximately 50 times the library size, were labeled
basically as described above, but with the addition of fluorescently
conjugated IgG in the second incubation for monitoring of the
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displayed library was sorted using a FACS Vantage SE (BD
Biosciences) flow cytometer. The sort gate was set to sort out the
top fraction of ABD-displaying cells showing the highest Alexa
Fluor 488 (TNF-a-binding through labeled streptavidin) to Alexa
Fluor 647 (IgG-binding) fluorescence intensity ratio. 1 mM
biotinylated TNF-a was used in the first round and concentrations
down to 1 nM in following rounds. Cells were sorted directly into
561 ml TSB+YE and thereafter inoculated to TSB+YE contain-
ing 10 mgm l
21 chloramphenicol and incubated at 37uC for
approximately 38 hours in order to amplify isolated cells by
growth for the next round of labeling and FACS. The procedure
was repeated three times using different concentrations of
biotinylated TNF-a and HSA conjugated to Alexa Fluor 488. In
experiments where the cell library was labeled with both TNF-a
and HSA, streptavidin conjugated to R-phycoerythrin was used
for detection of biotinylated TNF-a and HSA-Alexa Fluor 488
conjugate was added in the second incubation. After the third
sorting round, isolated cells were spread on agar plates and
selected variants were identified by DNA-sequencing.
Subcloning, expression, purification and characterization
of second-generation ABD-molecules
Six chosen candidate binders (ABDT001, ABDT002, ABDT004,
ABDHT014, ABDHT015 and ABDHT016) from the two selection
strategies were subcloned from the staphylococcal cell surface
display vector to the expression vector using specific oligonucle-
otide primers essentially as described above. The resulting
constructs were sequence verified and plasmids transformed into
E. coli Rosetta (DE3). Protein expression was carried out as
described above but purification was based on albumin binding by
HSA affinity chromatography. Pelleted bacteria were resuspended
in 10 ml tris-buffered saline (TST; 25 mM Tris-HCl, 200 mM
NaCl, 1 mM EDTA, 0.5% (w/v) Tween 20, pH 8.0) and
disrupted by sonication. The lysates were loaded on 4 ml HSA-
sepharose (Pharmacia Biotech) gravity flow columns equilibrated
with TST. The columns were washed with 20 CV TST followed
by 12 CV of 5 mM NH4Ac pH 5.5 and eluted by 0.5 M HAc in
1 ml fractions. Eluted fractions were dried by speedvac (Savant
AES2010, Thermo Scientific, MA, USA) over night, dissolved in
PBS and the purity was evaluated by SDS-PAGE. Concentrations
were determined by amino acid analysis (Aminosyraanalyscen-
tralen, Uppsala, Sweden) and molecular weights were verified by
LC-ESI-MS.
Biosensor analysis of second-generation binders
The binding kinetics of the six selected second-generation
molecules for the two targets were determined by SPR on a
ProteOn XPR36 Protein Interaction Array System (Bio-Rad, CA,
USA). The ABD-molecules were diluted to 10 mgm l
21 in 10 mM
NaAc pH 4.5 and immobilized by amine coupling on a ProteOn
GLM sensor chip (approximately 800–1500 RU) followed by
injection of dilution series of HSA or TNF-a (50 ml min
21 at 25uC
using PBS supplemented with 0.1% Tween 20 as running buffer).
The analysis was repeated at least in triplicates for each
interaction, on two different sensor chips (GLC in the second
run) and two different days using different dilution series of the
analytes (ranging from 1–100 nM for TNF-a and 7–1200 nM for
HSA).
In addition, simultaneous binding of the bispecific ABD-
molecules to HSA and TNF-a was investigated on a chip with
HSA immobilized in two flow cells to different surface densities. In
a first experiment 100 nM of the bispecific ABD-molecules
ABDT001 or ABDHT014 were injected over the HSA-surfaces
followed by injection of a dilution series of TNF-a (starting at
100 nM). Furthermore, 100 nM ABDT001 or ABDHT014 were
injected over the two surfaces and compared to 100 nM of the
same molecules pre-incubated for 10 min with a 20-fold molar
excess of TNF-a. A competition assay with a TNF-a-binding
affibody molecule (Z185; [24]) based on a closely related protein
scaffold was set up with one of the best performing TNF-a-binding
molecules (ABDT001). Both molecules were immobilized in
separate channels on a sensor chip and 100 nM TNF-a or
100 nM TNF-a pre-incubated for 10 min with a 20-fold molar
excess of ABDT001 or Z185 was injected. The responses from the




In order to generate new potentially bispecific affinity proteins,
a phage-displayed combinatorial library was used in biopannings
with TNF-a as target. The library is based on an alkali-stabilized
form of an albumin-binding domain (ABD) from streptococcal
protein G. Eleven positions on helix one and helix three that are
not involved in the inherent HSA interaction are randomized with
NNK degenerated codons (Fig. 1) [17]. Four rounds of biopanning
(A–D) against TNF-a were performed for isolation of binders, with
decreasing target concentration and an increasing number of
washes in each successive cycle (Fig. 2A). Sequencing of clones
from the third and the fourth round of panning revealed 19 unique
candidates, out of which six occurred more than once and were
therefore selected for further characterization. Moreover, the two
clones that occurred most frequently (denoted ABDTNF1 and
ABDTNF2) showed a high degree of sequence similarity (Fig. 2B)
and were also found in several parallel selection tracks, reflecting
independent enrichment.
Biosensor analyses of selected ABD-variants
To produce soluble ABD-variants for binding studies, the six
selected candidates were subcloned into a production vector
containing an N-terminal His6-tag. The corresponding proteins
were expressed in E. coli and purified to homogeneity. Correct
molecular weights were verified by LC-ESI-MS (data not shown).
The six ABD-variants were thereafter screened for binding to
TNF-a and HSA in an SPR-based biosensor assay, demonstrating
retained binding to HSA, although several had lower affinities
compared to the non-randomized ABD-molecule (data not
shown). Furthermore, the two most frequently observed candidates
in the sequencing (ABDTNF1 and ABDTNF2) were also binding to
immobilized TNF-a (Table 1), indicating that the biopanning had
been successful. The two candidates demonstrating dual binding
were immobilized on a new sensor chip and subjected to binding
analyses to determine their affinities to the two target proteins.
Apparent equilibrium dissociation constants for both target
molecules were obtained by non-linear regression of the SPR
data. ABDTNF1 showed a KD of approximately 400 nM for TNF-
a and 1900 nM for HSA (Table 1). Interestingly, ABDTNF2 had
instead a high affinity for HSA (17 nM) and a moderate apparent
affinity for TNF-a (1600 nM) (Table 1). Functional binding to
albumin was also verified for ABDTNF1 and ABDTNF2 in affinity-
chromatography purification, using immobilized HSA as ligand on
the matrix [25]. The purification was successful with no detectable
recombinant protein in the flow through and pure proteins of
correct size in the eluate (data not shown). In addition to verifying
the albumin-binding capacity of the two new variants, the results
also demonstrate that bispecific ABD-molecules can be produced
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PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25791Figure 1. Structure of the three-helical albumin-binding domain (ABD) from streptococcal protein G (PDB: 1GJT). Helices are
numbered as 1, 2 and 3 and indicated in the figure. A. Indicated in blue are amino acids on helix 2 and 3 (S18, Y20, Y21, K22, N23, L24, K29 and E32)
that have been suggested to participate in the interaction to albumin (defined as resulting in at least a 2-fold decrease in affinity when mutated to
alanine [16]). B. Indicated in green are amino acids on helix 1 and 3 that were targeted for randomization in the library. The library was designed in
order to randomize a surface that was non-overlapping with the positions that are interacting with albumin. C. Structure of ABD observed from
above with the albumin-interacting surface on helix 2 and 3 indicated in blue and the randomized surface on helix 1 and 3 indicated in green.
doi:10.1371/journal.pone.0025791.g001
Figure 2. Selection strategy for phage display enrichment of TNF-a-binding ABD-variants and sequences of bispecific first-
generation molecules. A. Four cycles of selection, split into four parallel tracks, were performed. The percentage of Tween 20 and the number of
washes were increased in each round of selection. Neutravidin coated paramagnetic beads (N) were used to capture phage-target complexes in
cycles 1-3, and in cycle 4 streptavidin coated beads (S) were used. B. Amino acid sequences of the bispecific variants ABDTNF1 and ABDTNF2 and the
number of times those clones were observed. Non-randomized ABD is shown as a reference and randomized positions are indicated with bullets.
doi:10.1371/journal.pone.0025791.g002
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which further reduces the size of the final affinity protein. This
production and purification strategy should be applicable to all
future bispecific ABD-based binders, regardless of their engineered
additional specificity.
On-cell evaluation and construction of a cell-displayed
affinity maturation library
To further characterize the two most promising anti-TNF-a
candidates from the phage display selection and to verify
functional expression on bacterial cells, staphylococcal surface
display was employed for an on-cell affinity measurement using
flow cytometry. Monomeric constructs of the two variants were
subcloned into a staphylococcal display vector for subsequent
transformation to the staphylococcal host and expression on the
cell surface (Fig. 3A and B). Staphylococcal cells displaying the
ABD-molecules in fusion with a dimeric Z-domain, were
incubated with different concentrations of biotinylated TNF-a
(4.3 to 12900 nM) or HSA-Alexa 488 conjugate (1.25–2500 nM,
concentrations up to 20 mM for ABDTNF1). As a reference, non-
randomized ABD was also subcloned, expressed and incubated
with the same dilutions of fluorophore-labeled HSA and TNF-a.
After washing and incubation with fluorescently labeled strepta-
vidin (for detection of TNF-a) cells were analyzed by flow
cytometry. The results showed a high surface expression level for
all three recombinant proteins as well as specific binding to TNF-a
and HSA for ABDTNF1 and ABDTNF2, while the non-randomized
ABD was only binding HSA and not TNF-a. Mean fluorescence
intensities (MFI) from the flow-cytometric analysis were fitted
using non-linear regression to a monovalent binding equation for
determination of KD values and the affinities were in concordance
with the affinities determined by SPR (Table 1).
Although the phage display selection was successful and yielded
two variants that demonstrated binding to both HSA and TNF-a,
the affinities were moderate and the candidate that was displaying
the highest apparent affinity for TNF-a had around 400-fold lower
affinity for HSA compared to the non-randomized ABD. To
further improve the ABD-variants, an affinity maturation library
was designed with the aim to primarily increase the affinity for
TNF-a (Fig. 4). However, the more challenging goal to engineer
high affinity to both TNF-a and HSA into the same binder was
also envisioned. The design was based on the two most prevalent
first generation binders that showed affinity to both HSA and
TNF-a. Three of the positions that were identical in ABDTNF1 and
ABDTNF2 were locked and the remaining eight of the previously
selected eleven positions were targeted for randomization,
although with less diversity in most positions (Fig. 4). This
diversification resulted in a library with a theoretical complexity of
approximately 6?10
6 variants. Since cell display provides the
ability to analyze the library for TNF-a- and HSA-binding
simultaneously in a flow cytometer, the Gram-positive bacterium
Staphylococcus carnosus was chosen as display host for the affinity
maturation [26]. In addition, cell display has proven particularly
suitable for affinity maturation efforts, mainly due to an excellent
affinity discrimination capacity during FACS [26,27,28]. The
library was transformed to staphylococci, yielding roughly 2?10
7
transformants, hence covering the theoretical complexity almost 3-
fold. 360 clones from the unsorted library were sequenced and
showed a good agreement compared with the design (data not
shown). Full-length ABD-sequences were found in 94% of the
sequenced clones, 4% contained an amber stop codon in a
randomized (NNK) position and less than 2% showed deletions,
duplications or mutations that were not in agreement with the
design. To determine the proportion of variants that had retained
a detectable HSA-binding after randomization, the library was
incubated with fluorescently labeled IgG as well as HSA and
thereafter analyzed in the flow cytometer. The analysis showed
that around 50% of the population was still able to bind to HSA,
suggesting that the library design was successful and indeed
targeted mainly to the part of ABD that is not involved in the
interaction with HSA as intended.
Flow-cytometric sorting for isolation of improved ABD-
molecules
For isolation of variants with improved affinity for TNF-a and
HSA respectively, the staphylococcal library was subjected to three
rounds of FACS with alternating rounds of amplification by cell
growth. In total, six sorting strategies with different TNF-a
concentrations were employed (I-VI, Fig. 5A). For two of the six
strategies (V-VI), the library was simultaneously incubated with
both TNF-a and HSA (labeled with different fluorophores) from
round two in order to actively sort for bispecific variants (Fig. 3B).
In all selection rounds, fluorescently labeled IgG was used for
surface expression normalization through binding to the dimeric
Z-domain. Selection stringency in terms of target concentration
and sorting parameters was increased with each sorting round and
typically the top 0.5–1% of the library, that demonstrated the
highest target-binding to surface expression ratio, was gated and
isolated for amplification and subsequent rounds of sorting
(Fig. 5A). One of the advantages with cell-based selection systems
Table 1. Affinities (KD) and kinetic parameters (ka and kd) for ABDTNF1, ABDTNF2 and non-randomized ABD.
SPR On-cell
HSA TNF-a HSA TNF-a







-1] [nM] [nM] [nM]
ABDTNF1 9.1?10
3 0.02 1850 7.8?10





4 0.04 1560 23 594
ABD 1.7?10
5 9.0?10
-4 5.3 - - - 19 -
(*)Saturation was not reached for the highest concentration (20 mM).
Binding to HSA and TNF-a was determined by surface plasmon resonance spectroscopy (SPR) or on-cell by flow cytometry. Kinetic constants from SPR-measurements
were measured on duplicate samples and KD calculated from the mean values. On-cell measurements were performed once for HSA and in duplicates for TNF-a.A l l
parameters for TNF-a are calculated from the concentration of monomeric protein.
doi:10.1371/journal.pone.0025791.t001
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target-binding cells in the flow cytometer. In this study, the
visualization of the target-binding properties of the library
revealed an enrichment of target-binding clones in each sorting
round (Fig. 5A). For the dual selections (V and VI), TNF-a and
HSA-binding was also monitored in an additional dot plot,
visualizing potential bispecificity of individual cells (Fig. 5B). The
bispecificity analysis revealed that after the first cycle, a majority of
the library was mostly monospecific, i.e. demonstrating a
detectable affinity for either TNF-a or HSA. However, after the
dual selection in cycle two, the bispecific population was
significantly enriched, thus verifying that efficient enrichment of
two distinct specificities may be obtained in one single sorting
using our strategy (Fig. 5B). It should be noted though that
detection of fluorescent signals corresponding to binding of both
HSA and TNF-a is only demonstrating simultaneous binding on
the cell level but not on a molecular level. This is due to the
multivalent display of recombinant proteins on the cell surface
where a part of the protein population might bind to HSA and
another part to TNF-a, resulting in signals in both fluorescence
channels. Such clones are indeed bispecific, but each single ABD-
molecule is not necessarily capable of simultaneous binding. In
addition, after the first cycle, a control experiment was performed
in which the library was incubated with only secondary reagent
(streptavidin-Alexa Fluor 488) to confirm that isolated clones were
specific for TNF-a and not streptavidin. The results showed no
binding and thereby verified that the enriched specificity was for
the target proteins. After three rounds of FACS, isolated cells were
spread on agar plates for sequencing and characterization of
individual candidates.
By sequencing in total 403 colonies from all of the six sorting
strategies, 23 unique ABD-variants were identified. The most
prevalent occurred 235 times and the least prevalent clones were
found only once (Fig. 6A). Interestingly, no overlap was seen
between sequences from the bispecific sortings (V and VI) and
sequences from the TNF-a sortings (I-IV), i.e. no clones identified
from sortings V and VI were found among the clones from
sortings I-IV and vice versa (Fig. 6A). In addition, the homology
between these two sets of sequences was also lower compared to
the homology within each set. For sorting strategies employing a
more stringent selection pressure with lower target concentration,
the number of different clones was lower, indicating a successful
and converging enrichment of high-affinity variants (Fig. 6A). Two
sequences with mutations in scaffold positions were observed
(ABDT013 and ABDHT021).
On-cell evaluation of second-generation binders
All the 23 clones were screened for binding to both TNF-a and
HSA at two concentrations each (10 and 150 nM). The analysis
was performed on the cell surface and the target-binding of each
variant was measured using flow cytometry. The analysis showed
that all selected clones bound their respective targets in a
concentration-dependent manner (data not shown). Interestingly,
all clones derived from the dual selection demonstrated a higher
relative affinity for HSA compared to the clones selected using
only TNF-a. However, variants with high TNF-a-binding signals
were found in all tracks, suggesting that the selection pressure for
bispecificity is affecting the selection but not limiting the affinity to
a very large extent. In summary, all 23 different isolated variants
were able to bind to both TNF-a and albumin in the flow
cytometer, demonstrating that the flow-cytometric sorting was
successful. Based on these results, the three best performing clones
from each strategy (ABDT001, ABDT002, ABDT004, ABDHT014,
ABDHT015 and ABDHT016) were selected for further on-cell
binding analyses using flow cytometry as well as expression and
subsequent HSA-affinity purification.
Binding to albumin has been shown to extend the in vivo half-
life of proteins, and is considered to have great potential as a
strategy for increasing the potency of biological drugs based on
small affinity proteins. This mechanism, which depends on
Figure 3. Staphylococcal display vector and schematic repre-
sentation of the cell-surface displayed ABD-library. A. Staphy-
lococcal display vector for display of heterologous proteins on the
surface of S. carnosus. Abbreviations: Z2, dimeric Z-domain gene; Bla,
beta-lactamase encoding gene; Cmlr, chloramphenicol acetyl transfer-
ase-encoding gene; OriE and OriS, origin of replication for E. coli and
staphylococci, respectively; PP, propeptide from S. hyicus lipase; PLip,
promoter from S. hyicus lipase. S, signal sequence from S. hyicus lipase;
XM, cell wall anchoring region from staphylococcal protein A. B.
Schematic representation of the recombinant ABD-library in fusion to
the dimeric Z-domain displayed on the staphylococcal cell surface. The
dimeric Z-domain functions as a reporter tag for monitoring of the
surface expression level of individual cells through binding to labeled
IgG. The target-binding signal can thereby be normalized with the
expression level in order to minimize expression bias during sorting.
Labeled proteins in the first and secondary incubations for the dual
selection are indicated in the figure.
doi:10.1371/journal.pone.0025791.g003
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endosomes, has been demonstrated for antibodies, albumin as
well as for various albumin-binding moieties [18,19]. In order to
get a first indication whether our new bispecific binders would be
suitable for in vivo applications, two experiments were performed,
assessing both the important pH-dependency as well as
evaluating if the ABD-variants could bind TNF-a in an excess
of albumin, thus mimicking the conditions in blood. In the first
experiment, the six selected binders were evaluated on the cell
surface to assess the pH-dependency of the HSA-interaction by
measuring the off rate from albumin at both pH 7.4 and 5.5. No
significant difference in dissociation rate from HSA could be
detected for the different bispecific variants when binding at
pH 7.4 was compared to pH 5.5 (data not shown), and the
results thus support the hypothesis that the bispecific molecules
may be able to utilize FcRn-mediated recycling for half-life
extension. In addition, the TNF-a-binding ability in presence of
an excess of HSA was evaluated to mimic the natural conditions
in vivo. Cells expressing the bispecific ABD-variants were first pre-
incubated with saturating concentrations of HSA before being
incubated with TNF-a in presence of a large excess of HSA. The
signal from the fluorescently labeled TNF-a was measured by
flow cytometry and the results showed that the TNF-a-binding
on-cell could be detected for all six variants, reaching almost the
same levels as without pre-incubation with HSA (data not
shown). Moreover, the TNF-a-binding signal in presence of a
large excess of HSA was higher for the variants with a lower
HSA affinity compared to variants from the dual selection that
exhibit a higher HSA affinity. The results hence indicate that the
binding of TNF-a interferes with albumin binding, but that the
stronger binding to TNF-a can compete with the interaction to
HSA. As expected, the TNF-a-binding capacity in presence of a
large excess of HSA was higher for the variants that were only
selected against TNF-a as compared to candidates from the dual
selection.
Affinity determination of bispecific candidates
In order to further investigate the ability of the domains to bind
the two different target proteins, the six selected second-generation
candidates were expressed in E. coli and affinity purified based on
their HSA-binding ability. The results demonstrated again that the
bispecific ABD-molecules could be expressed and efficiently
purified as single domains without an extra purification tag.
The soluble ABD-variants were immobilized on sensor chip
surfaces for determination of the affinities to TNF-a and HSA
using SPR (Fig. 6B). Kinetic evaluation of the binding of the six
ABD-variants to TNF-a revealed apparent KD values in the low
nanomolar range (down to 2.9 nM), which corresponds to a more
than 100-fold improvement in affinity compared to the best first-
generation binder (Table 1 and 2). In addition, the candidates
from the dual selection (ABDHT014, ABDHT015 and ABDHT016)
showed a high affinity to both targets, with around 5 nM apparent
affinities for TNF-a and 35–70 nM for HSA (Table 2). The results
thus demonstrate that using the dual selection strategy, the
relatively moderate affinity of the first-generation clones to TNF-a
and HSA, respectively, could be increased but also combined into
potent bispecific affinity proteins.
Binding assays
Although several of the isolated binders from the affinity
maturation had a high affinity to both TNF-a and albumin, it was
not possible to determine if they were able to bind the two targets
simultaneously from the on-cell experiments. In order to
investigate whether our binders were capable of simultaneous
binding, we performed two different biosensor assays. In the first
experiment, the bispecific proteins were injected over a surface
immobilized with HSA and followed by co-injections of TNF-a.I n
the second experiment, the bispecific proteins were instead pre-
incubated with TNF-a and thereafter injected over a surface
immobilized with HSA. No simultaneous binding could be
detected in any of the two assay formats. The results hence
indicate that the findings from the flow-cytometric assay, where
TNF-a-binding was detected in presence of an excess of HSA, was
indeed due to the much higher affinity for TNF-a compared to the
affinity for HSA (10 to 100-fold) and not due to simultaneous
binding. Even though the new bispecific binders demonstrated a
high affinity to both TNF-a and albumin, the results were not
surprising. The ABD-variants are comprised of only 46 amino
acids and both targets are relatively large, probably resulting in
sterical hindrance and thus no opportunity for simultaneous
binding. However, it is too early to draw any general conclusions
from this result and selections against other targets must be
performed to definitely assess the possibility of simultaneous
binding.
As mentioned above, ABD is a small domain with a three-
helical fold. Although it is not related in primary sequence, it
Figure 4. Randomized positions in the affinity maturation library (Sc:ABDTNFlib). A. Sequence in randomized positions of the first
generation binders ABDTNF1, ABDTNF2 and Sc:ABDTNFlib. B. Positions targeted for randomization indicated by light circles. Three positions randomized
in the initial library were omitted in the design, indicated by dark circles. The randomizations are listed beside the position. ARA = Arg, Lys. BBG =
Ala, Arg, Gly, Leu, Pro, Ser, Trp, Val. GAK = Asp, Glu. NYC = Ala, Ile, Leu, Phe, Pro, Ser, Thr, Val. NNK = all amino acids and one amber stop. The
theoretical size of the library is 6.6?10
6.
doi:10.1371/journal.pone.0025791.g004
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affibody molecules [11], which are derived from protein A. TNF-a
specific affibody molecules have been generated in a previous
study and due to their similar structure we wanted to investigate if
the two different classes of binders were directed against the same
epitope on TNF-a. Consequently, an SPR-based competition
assay was performed with the most prevalent bispecific protein
(ABDT001) and a well-characterized affibody molecule specific for
TNF-a [24]. The analysis showed that pre-incubation of TNF-a
with either of the binders efficiently blocked the interaction to the
other binder that was immobilized on a sensor chip surface (data
not shown). The results hence suggest that our new bispecific
binders are directed against the same epitope as the affibody
molecule, which is interesting since both affinity proteins are based
on small three-helix bundle scaffolds where the engineered binding
surface is accommodated on a rather flat surface.
Discussion
Small size and a long in vivo half-life are two important
properties for affinity proteins in many therapeutic applications.
Unfortunately, fulfilling both requirements is generally difficult, as
small size of the protein tends to result in a rapid excretion from
the body. However, the in vivo half-life of molecules can be
increased considerably by binding to human serum albumin
(HSA). Hence, a small bispecific molecule with capability to bind a
specific target protein and also HSA would potentially combine
the favorable features linked to small size with a prolonged half-life
in vivo. In order to generate molecules with those characteristics, an
alkali-stabilized variant of one of the albumin-binding domains
(ABD) from streptococcal protein G was used as starting molecule
for the construction of a combinatorial protein library. Guided by
the previously solved structure of a closely related albumin-binding
domain interacting with HSA [15] and by previously reported
alanine-scanning data of the ABD/HSA interaction [16], eleven
positions were targeted for randomization [17]. The selected
positions were distributed on helix one and helix three, i.e. on the
opposite side to the albumin-binding region, in order to increase
the probability of obtaining bispecific proteins (Fig. 1). The
resulting library was displayed on phage particles and subjected to
biopanning against the disease-related tumor necrosis factor-a
(TNF-a). Sequencing of isolated variants revealed two dominating
clones that were further characterized. Not surprisingly, the
apparent affinity for TNF-a was relatively moderate with a KD of
around 400 nM for the stronger variant and 1600 nM for the
weaker (Table 1). However, the binding capacity to HSA was still
detectable, although considerably decreased for one of the binders.
Interestingly, the variant exhibiting the strongest affinity for TNF-
a (ABDTNF1) showed a pronounced decrease in affinity for HSA,
which illustrates the challenge in engineering two high affinity
interactions into one small domain. The interactions were also
analyzed by flow cytometry with the binding molecules displayed
on staphylococcal cells, demonstrating affinity for both TNF-a and
HSA, and at the same time establishing the utility of this platform
for further improvements (Table 1, Fig. 3). In order to primarily
increase the apparent affinity for TNF-a and potentially combine
high affinity for both TNF-a and HSA in one binder, an affinity
maturation library was designed, subcloned and expressed on the
surface of staphylococci. The choice of cell display over phage
display for the affinity maturation was based on several potential
advantages with the former. First, cell display in combination with
quantitative FACS is particularly powerful for affinity maturation
purposes, where improved second-generation variants must be
discriminated from a background of binders with moderate affinity
[26,27,28]. Moreover, the possibility of monitoring several
parameters simultaneously in the flow cytometer enables sorting
for bispecific binders that show binding to both targets in the same
sorting cycle. The library design was based on the two bispecific
candidates isolated by the phage display selection, resulting in a
theoretical complexity of almost seven million variants (Fig. 4).
Prior to FACS, the cell library was incubated with TNF-a and IgG
labeled with two different fluorophores. This provided means to
monitor the surface expression level of individual cells and thereby
perform normalization for fine affinity discrimination. In later
selection cycles, the labeling complexity was further increased by
employing a dual selection strategy in order to simultaneously
detect: i) bound TNF-a, ii) bound HSA and iii) surface expression
level (bound IgG) of every individual cell, which the sorting was
based on. Enrichment of target-binding cells was demonstrated
already in the flow cytometer after respective sorting cycle. After
three rounds of FACS, genes of displayed proteins of individual
cells were sequenced for identification of improved candidates
(Fig. 5A). Interestingly, in cycle two, the three-color labeling
revealed that the majority of the clones in the library were not able
to bind to both TNF-a and HSA, showing only binding to either
one of them. However, after applying a two-gate sorting to isolate
cells with affinity for both TNF-a and HSA (strategies V and VI),
the double-positive population was significantly enriched in
subsequent rounds (Fig. 5B). Moreover, sequencing of these cells
revealed a unique set of candidates with relatively low homology
compared to the set isolated solely for TNF-a-binding (Fig. 6A).
On the other hand, the bispecific binders showed a high similarity
to the first-generation binder exhibiting the strongest HSA affinity
(ABDTNF2). The TNF-a and HSA affinities of the clones showing
highest signals in a first screening experiment were determined by
surface plasmon resonance spectroscopy. In terms of TNF-a-
binding, the analysis revealed low nanomolar affinities corre-
sponding to around a 100-fold improvement for the best
performing candidate compared to the best first-generation clone
(Table 2). Interestingly, strong TNF-a binders were isolated from
both the selection using only TNF-a as target and the dual
strategy, suggesting that retaining the high affinity for HSA does
not necessarily limit the affinity for TNF-a. Bispecific binders with
affinities below 40 nM for HSA and around 5 nM for TNF-a were
isolated, demonstrating the power of the new dual sorting strategy.
Although similar results may have been achieved using phage
display and alternating rounds of selection to respective target, the
possibility of using multiparameter sorting and monitoring of the
library during selection makes cell display particularly well suited
for these efforts. Even though the binding to HSA was measurable
for a large part of the variants in the maturation library, the
randomization and selection resulted in rather low affinity for
Figure 5. Density plots showing the results from flow-cytometric sortings of Sc:ABDTNFlib.A . The density plots are showing the
staphylococcal library before flow-cytometric sorting round 1, 2 and 3, respectively, with regions used for gating outlined in each plot. The target
protein and the concentration used in each sorting are indicated on top of respective density plot. FL-4 channel fluorescence intensity corresponding
to surface expression level (monitored via IgG-binding) on the x-axis and FL-1 channel fluorescence corresponding to TNF-a- or HSA-binding on the
y-axis. B. Density plots showing the analysis of bispecificity of Sc:ABDTNFlib in cycle 2 and cycle 3 (incubated with 100 nM TNF-a and 300 nM HSA). FL-
1 channel fluorescence intensity corresponding to HSA-binding on the x-axis and FL-2 channel fluorescence corresponding to TNF-a-binding on the
y-axis.
doi:10.1371/journal.pone.0025791.g005
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randomized ABD is shown on top with the eight positions subjected to randomization in Sc:ABDTNFlib indicated. Boxes denote the localization of the
three helices in the structure of the parental ABD-molecule. The candidates are named and grouped according to selection strategy. Variants from
selections targeting only TNF-a (tracks I-IV, ABDT001-013) and from the dual-selection (tracks V-VI, ABDHT014-023) are shown. The columns to the right
indicate the number of times each clone was identified by DNA-sequencing and the selection track(s) from where the sequence originated. B.
Representative sensorgrams from SPR-analysis of immobilized ABDT001 and ABDHT014 binding to TNF-a and HSA. TNF-a was injected at
concentrations ranging from around 6–100 nM and HSA from 10–180 nM, data are double referenced by subtraction of simultaneous responses from
interspots and a buffer injection.
doi:10.1371/journal.pone.0025791.g006
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only against TNF-a (Table 1 and 2). However, in a recently
published study, Nygren and coworkers were able to improve the
binding between ABD and HSA almost 1,000,000-fold, i.e. down
to femtomolar affinity [29]. Interestingly, one of the beneficial
mutations (K35E) discovered in that paper was also enriched after
the dual selection, indicating that simultaneous improvement of
both interaction surfaces is possible. If necessary, grafting more of
these mutations into the candidates generated here might further
improve the affinity for HSA for our clones as well. On the other
hand, recent studies have demonstrated that even a weak or
moderate affinity for albumin is sufficient to achieve half-life
extension [30]. Interestingly, the six selected clones all demon-
strate ability to bind TNF-a in the presence of high concentrations
of HSA, despite the inability to bind both targets simultaneously.
This is due to the much higher affinity towards TNF-a than HSA
for all our binders. However, which affinities that will be optimal in
vivo and if simultaneous binding is a prerequisite, is something that
must be investigated further using appropriate animal models. In
summary, by using a combination of phage and cell display,
engineering of bispecificity into a 5 kDa small albumin-binding
domain has been possible. To our knowledge, the obtained binders
in this study are the smallest engineered bispecific proteins
reported so far and are probably close to the size limitation in
terms of obtaining two high affinity interacting surfaces on a single
protein. Furthermore, the demonstrated approach should be
applicable for generating bispecific affinity proteins to other
interesting targets, providing potentially outstanding tissue pene-
tration properties combined with a long in vivo half-life. Our data
also suggest that since the two surfaces are discriminated from
each other, the two affinities are independently tunable. The same
target-specific binder could thus be optimized for both imaging
applications, demanding short half-life, and therapeutics where
long half-life is desired.
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